首页|利福平联合复方新诺明对复治涂片阳性肺结核炎性因子的影响

利福平联合复方新诺明对复治涂片阳性肺结核炎性因子的影响

Effect of rifampicin combined with compound neotamine on proinflammatory factors in patients with retreated smear-positive pulmonary tuberculosis

扫码查看
目的 分析利福平联合复方新诺明辅助治疗对复治涂片阳性肺结核患者疗效和血清炎性因子水平的影响.方法 将2017年5月—2022年8月我院收治80例复治涂片阳性肺结核患者使用随机信封法分为观察组及对照组各40例.对照组采用利福平治疗,观察组采用利福平联合复方新诺明辅助治疗;治疗后对患者临床疗效、复发率及痰菌阴转率进行评估,并检测治疗前后血清炎性因子水平.结果 治疗后观察组病灶吸收率90.00%高于对照组77.50%,空洞缩小率95.00%高于对照组82.50%,差异均具有统计学意义(均P<0.05);观察组复发率2.50%低于对照组15.00%,痰菌阴转率97.50%高于对照组80.00%,差异均具有统计学意义(均P<0.05);观察组治愈率95.00%高于对照组85.00%,差异具有统计学意义(P<0.05).治疗后观察组血中白细胞介素-37(IL-37)、触珠蛋白(HP)、骨桥蛋白(OPN)水平均下降,观察组3种因子水平分别为(4.63±0.83)pg·mL-1、(810.38±31.64)μg·mL-1、(189.19±20.74)pg·mL-1低于对照组的(6.33±0.91)pg·mL-1、(1283.73±101.67)μg·mL-1、(456.28±45.92)pg·mL-1,差异均具有统计学意义(均P<0.05).结论 利福平联合复方新诺明对复治涂片阳性肺结核患者后有助于提高临床疗效,改善血液中IL-37、HP、OPN水平.
Objective To analyze the curative effect of rifampicin combined with compound neotamine in patients with retreated smear-positive pulmonary tuberculosis and its effect on serum levels of proimflammatory factors.Methods Eighty patients with retreated smear-positive pulmonary tuberculosis admitted to our hospital from May 2017 to August 2022 were randomly divided into observation group and control group by sealed envelopes.The control group was treated with rifampicin,while the observation group was treated with rifampicin combined with compound nectarine.After treatment,the clinical efficacy,recurrence rate and sputum negative conversion rate were evaluated,and the levels of HP(haptoglobin),IL-37(Interleukin-37)and OPN(osteopontin)in serum were detected before and after treatment.Results After treatment,the absorption rate of lesions in the observation group was significantly higher than that in the control group(P<0.05);the cavity shrinkage rate in the observation group was significantly higher than that in the control group(P<0.05);the recurrence rate of the observation group was significantly lower than that of the control group(P<0.05),and the sputum negative conversion rate was significantly higher than that of the control group(P<0.05).The prognosis of the observation group was significantly higher than that in the control group(P<0.05);the levels of IL-37,HP and OPN in both groups significantly decreased after treatment(P<0.05),the levels of IL-37,HP and OPN in the observation group were(4.63±0.83)pg·mL-1,(810.38±31.64)μg·mL-1,(189.19±20.74)pg·mL-1 in the control group were(6.33±0.91)pg·mL-1,(1283.73±101.67)μg·mL-1,(456.28±45.92)pg·mL-1 respectively,and the differences were statistically significant(P<0.05).The average was significantly lower than that of the control group(P<0.05).Conclusion Rifampicin combined with compound neotamine can improve the clinical efficacy of retreated smear-positive pulmonary tuberculosis patients,and significantly improve the levels of IL-37,HP and OPN in blood.

RifampicinCompound neotamineRetreatment smear-positive tuberculosisHaptoglobininterleukin-37Osteopontin

陈巧玲、陈炘、叶姿、罗卿、夏旭辉、刘发彬、王超秀、刘鑫、陈明惠

展开 >

内江市第一人民医院感染肝病科,内江 641000

利福平 复方新诺明 复治涂片阳性肺结核 触珠蛋白 白细胞介素-37 骨桥蛋白

2024

中国药物应用与监测
中国人民解放军总医院

中国药物应用与监测

CSTPCD
影响因子:1.983
ISSN:1672-8157
年,卷(期):2024.21(1)
  • 22